Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Weekly Recap: Apogee buy adds zumi asthma entry and SKYRIZI U.S. approval

21 September 2026 · By · Wire by Fusion42

Published

21 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 21 September 2026 · Fusion42 review

AbbVie acquired Apogee Therapeutics, adding the late-stage drug zūmi for atopic dermatitis and potential asthma treatments, and expects U.S. approval for SKYRIZI subcutaneous induction in Crohn’s disease in Q4, expanding its immunology portfolio.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now target AbbVie's expanded immunology pipeline including zūmi and upcoming SKYRIZI Crohn’s disease approval. Prepare to engage with payer access changes that open a wider U.S. market within 60-90 days.

◆ Coverage

1 source · 21 Sep 2026

◆ Related on Wire

◆ Topics

Biotechabbvieapogee-therapeuticszumiskyrizius-fda-approvalimmunology